First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
1. 系统已在2026-01-01 16:01:28对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.medj.2024.09.002
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2666634024003441
其他信息:
出版社: Elsevier BV
作者: Qing Zhou; Yan Yu; Ligang Xing; Ying Cheng; Ying Wang; Yueyin Pan; Yun Fan; Jianhua Shi; Guojun Zhang; Jiuwei Cui; Jianying Zhou; Yong Song; Wu Zhuang; Zhiyong Ma; Yanping Hu; Gaofeng Li; Xiaorong Dong; Jifeng Feng; Shun Lu; Jingxun Wu; Juan Li; Longzhen Zhang; Dong Wang; Xinhua Xu; Tsung-Ying Yang; Nong Yang; Yubiao Guo; Jun Zhao; Yu Yao; Diansheng Zhong; Bing Xia; Cheng-Ta Yang; Bo Zhu; Ping Sun; Byoung Yong Shim; Yuan Chen; Zhen Wang; Myung-Ju Ahn; Jie Wang; Yi-Long Wu
